Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6163157 | 0.91 | CYP3A4 (0.48) | GRM2CYP3A4GRM3RAB9ASMN1; SMN2 | |
| SCHEMBL6165896 | 0.90 | GRM2 (0.52) | GRM2CYP3A4GRM3 | |
| SCHEMBL6166237 | 0.89 | GRM2 (0.47) | GRM2CYP3A4GRM3RAB9ASMN1; SMN2 | |
| SCHEMBL6168265 | 0.89 | GRM2 (0.51) | GRM2CYP3A4GRM3 | |
| SCHEMBL6167964 | 0.88 | GRM2 (0.49) | GRM2 | |
| SCHEMBL6164771 | 0.87 | GRM2 (0.49) | GRM2CYP3A4GRM3 | |
| SCHEMBL6165660 | 0.87 | GRM2 (0.48) | GRM2CYP3A4 | |
| SCHEMBL6164969 | 0.86 | GRM2 (0.54) | GRM2CYP3A4 | |
| SCHEMBL6167304 | 0.86 | CYP3A4 (0.58) | GRM2CYP3A4GRM3 | |
| SCHEMBL6166489 | 0.86 | GRM2 (0.45) | GRM2CYP3A4GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379511-B1 | DIHYDRO-BENZO (b) (1, 4) DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS II | HOFFMANN LA ROCHE (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-6544985-B2 | For therapy of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits | HOFFMAN-LA ROCHE INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193367-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | CYP1B1, GRIN2B, BDKRB1 | GRM2 125/4885CYP3A4 190/4885GRM3 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.